Related Articles
Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation
Comparison of the efficacy of first‑/second‑generation EGFR‑tyrosine kinase inhibitors and osimertinib for EGFR‑mutant lung cancer with negative or low PD‑L1 expression
Successful treatment of non‑small‑cell lung cancer with afatinib and a glucocorticoid following gefitinib‑ and erlotinib‑induced interstitial lung disease: A case report
Osimertinib (AZD9291) increases radio‑sensitivity in EGFR T790M non‑small cell lung cancer
Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)